InvestorsHub Logo
Followers 33
Posts 1496
Boards Moderated 0
Alias Born 12/06/2016

Re: None

Saturday, 11/21/2020 2:18:53 PM

Saturday, November 21, 2020 2:18:53 PM

Post# of 35961
Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally.

Do your research, take your position, turn off the noise.


Real wealth is made riding the story.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RBSH News